A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult

NCT06313697 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: GR2102 injection
BIOLOGICAL: placebo

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.